Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Q-Pan H5N8 Influenza Vaccine in Adults
NCT05975840Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of H5N8 antigen + AS03A in influenza A virus H5N8 infection (H5N8), sponsored by GSK. Started Aug 2023; status: completed.
02
Drugs
H5N8 antigen + AS03A
03
Conditions
influenza A virus H5N8 infection (H5N8)
Beyond the preview
Go deeper on NCT05975840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975840.